Home › Research › Tau biomarkers
Soluble TREM2 and Alzheimer-related biomarker trajectories in the blood of patients with diabetes based on their cognitive status
Satoh-Asahara N, Yamakage H, Tanaka M, Kawasaki T, Matsuura S, Tatebe H, Akiguchi I, Tokuda T.. Diabetes research and clinical practice, 2022-10-20
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Aim We aimed to elucidate the dynamics of blood biomarkers according to the severity of cognitive impairment in patients with type 2 diabetes mellitus (DM) and to identify useful biomarkers for diabetes-related dementia. Methods This was a cross-sectional, nested case-control study of 121 Japanese DM and non-DM patients with different levels of cognitive functioning. We evaluated participants' cognitive functions, blood biomarkers related to Alzheimer's disease, and soluble triggering receptors expressed on myeloid cells 2 (sTREM2).
What this study adds
Evidence grade: Moderate
This is a case-control study. This study compared blood markers, including soluble TREM2, in people with and without type 2 diabetes across different levels of cognitive function. It found significantly lower levels of serum sTREM2 in all cognitive strata, but it is a cross-sectional study and does not show whether this marker can be used to treat or prevent dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Satoh-Asahara, N., Yamakage, H., Tanaka, M., Kawasaki, T., Matsuura, S., Tatebe, H., et al. (2022). Soluble TREM2 and Alzheimer-related biomarker trajectories in the blood of patients with diabetes based on their cognitive status. Diabetes research and clinical practice. https://doi.org/10.1016/j.diabres.2022.110121
Vancouver
Satoh-Asahara N, Yamakage H, Tanaka M, Kawasaki T, Matsuura S, Tatebe H, et al. Soluble TREM2 and Alzheimer-related biomarker trajectories in the blood of patients with diabetes based on their cognitive status. Diabetes research and clinical practice. 2022. doi:10.1016/j.diabres.2022.110121. PMID: 36272585.
BibTeX
@article{satohasahara2022-36272585,
author = {Satoh-Asahara, N. and Yamakage, H. and Tanaka, M. and Kawasaki, T. and Matsuura, S. and Tatebe, H. and Akiguchi, I. and Tokuda, T.},
title = {{Soluble TREM2 and Alzheimer-related biomarker trajectories in the blood of patients with diabetes based on their cognitive status}},
journal = {Diabetes research and clinical practice},
year = {2022},
doi = {10.1016/j.diabres.2022.110121},
pmid = {36272585},
url = {https://doi.org/10.1016/j.diabres.2022.110121}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Methods This was a cross-sectional, nested case-control study of 121 Japanese DM and non-DM patients with different levels of cognitive functioning.
- We evaluated participants' cognitive functions, blood biomarkers related to Alzheimer's disease, and soluble triggering receptors expressed on myeloid cells 2 (sTREM2).
- We then compared these biomarkers between the DM and non-DM and across the different cognitive strata.
- Results In all cognitive strata, significantly lower levels of serum sTREM2 were observed in the DM than in the non-DM.
Why it matters
This study compared blood markers, including soluble TREM2, in people with and without type 2 diabetes across different levels of cognitive function. It found significantly lower levels of serum sTREM2 in all cognitive strata, but it is a cross-sectional study and does not show whether this marker can be used to treat or prevent dementia.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcase-control study
- Evidence strengthModerate
How this study scored 45/100
Published in a peer-reviewed journal, and it is a case-control study. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Diabetes research and clinical practice) |
| Journal's citation record | 2 / 4 | Diabetes Research and Clinical Practice: journal h-index 181 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 15 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 2 / 6 | Cited 1.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Takahiko Tokuda: h-index 49 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Nagoya University: institution h-index 758 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36272585) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.diabres.2022.110121
- PubMed: 36272585
- Original source →
- Free full text: Diabetes Research and Clinical Practice →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Related studies in Tau biomarkers from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.